Wednesday, July 8, 2026

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin

3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7
Clinical program

TGR-1202

Phase 1 · small molecule · Non-Hodgkin's Lymphoma

TGR-1202 for Non-Hodgkin's Lymphoma is a Phase 1 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All TG THERAPEUTICS, INC. projects Phase 1 small molecule completed

Internal code TGR-1202-101 (HEMREF 31)

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
TG THERAPEUTICS, INC.
Phase
Phase 1
Modality
small_molecule
Indication
Non-Hodgkin's Lymphoma
Status
completed
Trials
1

Clinical trials